Neil Solomons - Nov 9, 2021 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Signature
/s/ Neil Solomons, M.D.
Stock symbol
AUPH
Transactions as of
Nov 9, 2021
Transactions value $
-$6,395,100
Form type
4
Date filed
11/12/2021, 03:13 PM
Previous filing
Nov 3, 2021
Next filing
Mar 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Shares Sale -$1.51M -50K -36.42% $30.17 87.3K Nov 9, 2021 Direct F1, F2
transaction AUPH Common Stock Options Exercise $424K +70K +80.18% $6.06 157K Nov 10, 2021 Direct F3
transaction AUPH Common Stock Options Exercise $159K +30K +19.07% $5.30 187K Nov 10, 2021 Direct F3
transaction AUPH Common Stock Sale -$2.81M -90K -48.05% $31.17 97.3K Nov 10, 2021 Direct F1, F4
transaction AUPH Common Stock Sale -$306K -10K -10.28% $30.55 87.3K Nov 10, 2021 Direct F1, F5
transaction AUPH Common Stock Options Exercise $530K +100K +114.55% $5.30 187K Nov 11, 2021 Direct F3
transaction AUPH Common Stock Sale -$2.89M -100K -53.39% $28.89 87.3K Nov 11, 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Stock Option (right to buy) Options Exercise $0 -70K -100% $0.00* 0 Nov 10, 2021 Common Stock 70K $6.06 Direct F3, F7
transaction AUPH Stock Option (right to buy) Options Exercise $0 -30K -23.08% $0.00 100K Nov 10, 2021 Common Stock 30K $5.30 Direct F3, F8
transaction AUPH Stock Option (right to buy) Options Exercise $0 -100K -100% $0.00* 0 Nov 11, 2021 Common Stock 100K $5.30 Direct F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
F4 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.00 to $31.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.30 to $30.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.50 to $29.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The shares subject to the option vest in twenty-four equal monthly installments from the grant date.
F8 The shares subject to the option vest in thirty-six equal monthly installments from the grant date.